EAU 2013 - Programme Book - YouMed

856 Reducing the number of prostate biopsies – validation of a four kallikrein panel to predict prostate cancer
in a population-based referral cohort
K. Braun, H.G. Lilja, A.J. Vickers, D. Sjoberg, A. Bjartell (Herne, Germany; New York, United States of
America; Malmö, Sweden)
857 Relationship between PSA level and impairment of proteinase-inhibitory balance of key proteolytic
systems during androgen-deprivation therapy for prostate cancer
M.I. Kogan, M.B. Chibichyan, E.A. Chernogubova (Rostov on Don, Russia)
858 Baseline PSA level in prediction of prostate cancer risk and aggressiveness: A Danish population-based
cohort study
S. Benzon Larsen, K. Brasso, S.O. Dalton, J. Christensen, M. Christiansen, S. Calsson, H. Lilja, S. Friis,
A. Tjønneland, P. Iversen (Copenhagen, Denmark; New York, United States of America)
859 Parallel measurement of urinary PCA3 and TMPRSS2:ERG with serum [-2]proPSA based Phi for prostate
cancer detection
C. Stephan, A. Semjonow, K. Schulze-Forster, H. Cammann, X. Hu, K. Miller, K. Jung, F. Friedersdorff (Berlin,
Münster, Luckenwalde, Germany)
860 Influence of metabolic syndrome on prostate volume and prostate specific antigen
W.S. Choi, C.J. Lee, S.B. Ha, S.Y. Cho, N.J. Heo, H. Jeong, J.S. Paick, H. Son (Seoul, South Korea)
861 Chemopreventive properties of the flavonoids genistein and quercetin in men with rising PSA: First results
of a double-blind, randomized, placebo-controlled trial (QUERGEN trial)
A. Galasso, S. Aufderklamm, A. Damms-Machado, F. Miller, S.C. Bischoff, A. Stenzl, G. Gakis (Hohenheim,
Tübingen, Germany)
EAU Milan 2013
273
Monday